In patients with heart failure with improved ejection fraction (EF), pharmacological therapy is rarely withdrawn, according to a study published online March 17 ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...

"Our results show that heart failure medications continue to provide ... "This supports the current recommendation to continue with RASi/ARNi and MRA treatment, but also opens up the possibility ...

"Our results show that heart failure medications continue to provide ... "This supports the current recommendation to continue with RASi/ARNi and MRA treatment, but also opens up the possibility ...

Withdrawing RASi/ARNi and MRA was associated with higher mortality/morbidity at 1 year ... the need for randomized controlled trials testing BBL withdrawal in patients with HF with improved EF. In ...

Right-sided heart failure develops when the right side of the heart is too weak to pump blood to the lungs. This causes blood to back up into the venous system, limiting how much blood the heart can ...

Apr. 3, 2025 — There are over six million Americans with heart failure who are at greater risk of losing their cognitive abilities earlier in life, a study suggests. Global cognition and ...

The following is a summary of "Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart failure: findings from the EARLIER trial," published in the March 2025 issue of ...